Omilancor (BT-11) is a direct LANCL2 (Lanthionine Synthetase Cyclase-Like 2) activator with oral activity for the treatment of Crohn's Disease (CD), Inflammatory Bowel Disease (IBD) and Ulcerative Colitis (UC).

Omilancor was tested on mouse splenocytes (WT and LANCL2⁻/⁻) to evaluate cAMP production after treatment (dose-dependent). Omilancor increased intracellular cAMP in WT cells but had no effect in LANCL2-deficient cells, indicating target-specific activation[1].

In DSS-induced colitis mouse models, Omilancor was administered orally (8 mg/kg/day; 7 days). Omilancor significantly reduced disease activity index and gut inflammation, lowered TNF-α, increased IL-10, and restored LANCL2 expression in colonic tissue. Efficacy was abolished in LANCL2⁻/⁻ mice, confirming target specificity[1].